Conn., March 25 /PRNewswire-FirstCall/ -- 454 Life
Sciences, a majority-owned subsidiary of CuraGen Corporation
(Nasdaq: CRGN - News), announced today that it has
sold and installed its first 454 Genome Sequencing
System at the Genome Sequencing and Analysis program
of the Broad Institute of MIT and Harvard, a research
collaboration of the Massachusetts Institute of Technology,
Harvard University and its hospitals and the Whitehead
Institute for Biomedical Research. The system, which
utilizes novel technology developed by 454 Life Sciences,
has the potential to perform sequencing 100 times
faster than conventional sequencing machines.
sequencing technology is entering a new era of development,"
said Eric Lander, Ph.D., director of the Broad Institute.
"The 454 Genome Sequencing System is the first
of this next generation and we expect it to enable
our researchers to tackle a wide range of applications."
"We are honored to have the first 454 Genome
Sequencing System installed at the Broad Institute.
The power of our system lies in its use of nanotechnology
and microfluidics to allow massively parallel genomic
sequencing, creating the potential for a single instrument
to replace dozens of conventional sequencing machines,"
stated Christopher K. McLeod, interim President and
CEO of 454 Life Sciences. "We look forward to
a productive relationship with the Broad as this new
era of genomic sequencing begins, and anticipate that
it will shape the future of this technology and applications
for its use in genomics research."
Chad Nusbaum, Ph.D., co-director of the Broad Institute
Genome Sequencing and Analysis program, added "Our
production team is enthusiastic about using the 454
system and we're excited about the potential of this
technology to embark upon a variety of projects at
The Broad Institute is the first institution in the
world to receive the 454 Genome Sequencing System
and will be utilizing proprietary system reagents
sold by 454 Life Sciences for several ongoing projects.
The Broad Institute is a member of 454's Early Access
Program, which enables select clients to work with
454's technology and instrumentation at 454's Measurement
Service Center, as well as giving them the ability
to obtain the first commercially available systems.
454 Life Sciences provides whole genome sequencing
solutions including instruments and reagents, as well
as sequencing services to a broad range of customers.
Since early 2004, 454 Life Sciences' Measurement Service
Center, located in Branford, CT, has routinely sequenced
whole genomes for clients worldwide using 454's proprietary
technology and instruments. In addition to service-based
genomic analysis, the Measurement Service Center provides
training for researchers and staff using the 454 Genome
454's technology represents the first new approach
for genomic sequencing to be commercialized in more
than 20 years. 454's system enables one individual
to prepare and sequence an entire genome after performing
a single sample preparation, irrespective of the size
of the genome being studied. The hallmark of 454's
technology is the radically different approach to
sequencing which allows a single instrument to produce
over 20 megabases (20,000,000 bases) of sequencing
per four hour run, totaling more that 100 times the
capacity of instruments using the current standard
technology. 454's technology is based on proprietary
picoliter-technologies, patented light emitting sequencing
chemistries, and state of the art informatics. The
patented Genome Sequencing System utilizes this technology
and is a scalable, ultra-fast and cost-effective system
for whole genome sequencing.
About 454 Life Sciences
454 Life Sciences is commercializing novel instrumentation
and services for rapidly and comprehensively determining
the nucleotide sequence -- "whole genome sequencing"
-- of genomes. The Company's instrument systems, based
on proprietary picoliter-technologies, patented light
emitting sequencing chemistry, and state of the art
informatics, have 100 times the throughput of existing
sequencing machines. 454 is marketing its services
and instruments to pharmaceutical, biotechnology,
biodefense, and agriculture companies as well as to
universities and government agencies. 454 Life Sciences
is a majority owned subsidiary of CuraGen Corporation.
Additional information is available at http://www.454.com/.
Life Sciences Contact:
Christopher K. McLeod